Clinical Report: Mitigating Ocular Surface Disease in Patients With Glaucoma

Overview

This report emphasizes the importance of evaluating glaucoma patients for ocular surface disease (OSD) due to the adverse effects of eyedrop therapy. It highlights the need for alternative treatment strategies to improve patient adherence and visual outcomes.

Background

Ocular surface disease is prevalent among glaucoma patients, with over half experiencing chronic symptoms due to the toxicity of topical medications. The destabilization of the tear film can lead to significant discomfort and visual impairment, making it critical for eyecare providers to assess and address OSD. Effective management of OSD not only enhances patient comfort but also promotes adherence to glaucoma therapies.

Data Highlights

No numerical data provided in the source material.

Key Findings

• More than 50% of glaucoma patients experience chronic ocular surface disease due to eyedrop therapy.
• 40% of patients preparing for cataract surgery had corneal staining, with 85% being asymptomatic.
• Non-drop therapies, such as intracameral implants and selective laser trabeculoplasty, can effectively manage intraocular pressure without exacerbating OSD.
• Minimally invasive glaucoma surgery (MIGS) offers a viable option for patients requiring surgical intervention without the complications associated with traditional glaucoma surgery.
• Screening for OSD at the first glaucoma consultation is essential for effective management.

Clinical Implications

Eyecare providers should routinely evaluate glaucoma patients for ocular surface disease to ensure optimal treatment outcomes. Utilizing non-drop therapies and minimally invasive surgical options can significantly reduce the burden of ocular surface disease and improve patient adherence to glaucoma medications.

Conclusion

Addressing ocular surface disease in glaucoma patients is crucial for maintaining visual health and medication adherence. Implementing proactive screening and alternative treatment strategies can enhance patient care.

References

1. Laura Voicu, MD, Sarwat Salim, MD, FACS, Glaucoma Physician, 2023 -- Treatment of Severe Ocular Surface Disease in the Glaucoma Patient Recommendations
2. Ophthalmology Management, 2018 -- The Role of MIGS to Manage Glaucoma in the Dry Eye Patient
3. Ophthalmology Management, 2017 -- Ocular Surface Disease and Glaucoma
4. American Optometric Association, 2024 -- EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE Care of the Patient
5. PMC, 2024 -- A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension
6. JAMA Ophthalmology, 2023 -- Shedding LiGHT on Selective Laser Trabeculoplasty
7. EVIDENCE-BASED CLINICAL PRACTICE GUIDELINECare of the Patient
8. A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension - PMC
9. Shedding LiGHT on Selective Laser Trabeculoplasty | Glaucoma | JAMA Ophthalmology | JAMA Network